Update on Hepatitis B Management: New Data From EASL

[Guest guest]

> *CCO is an independent medical education company that provides

state-of-the-art medical information to healthcare professionals through

conference coverage and other educational programs.

>

> Independent Online Conference Coverage

> Click to Access

> Update on Hepatitis B Management

> CCO Independent Conference Coverage of the

> 2008 Annual Meeting of the European Association for the Study of the Liver*

> April 23-27, 2008 | Milan, Italy

>

> Click to Access

> Expert Highlights in MP3 Format

> Listen to the experts summarize the most important data from EASL with our

exclusive CCO Podcasts!

>

> These audio files are in mp3 format. To listen to the audio, simply click

" Download Audio. " You must be logged onto the clinicaloptions.com site to

download the mp3 files.

>

> [http://clinicaloptions.com/upload/global/headshots/buti_maria.jpg]

>

> Buti-Ferret, MD, discusses key efficacy and resistance HBV data

presented at the meeting in Milan, including reports in treatment-naive patients

and strategies for patients with resistance. (12 minutes)

> [http://clinicaloptions.com/images/trackarrow_hep.gif]

>

>

> Click to Access

> Download Audio

>

>

>

> These Expert Highlights are located online at:

> http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Milan%202008.aspx

>

>

[http://images.clinicaloptions.com/img.asp?img=cco_bar/bar_hep_capsule_summaries\

..gif]

>

> Click a link below to access a Capsule Summary:

>

> * Rapid, Persistent HBV DNA Suppression With Tenofovir Treatment in

HBeAg-Negative Chronic Hepatitis B

>

> * Continued Efficacy With Tenofovir Through Week 72 of Therapy in

HBeAg-Positive Patients

>

> * Tenofovir Appears Safe and Effective in Treatment-Experienced Hepatitis B

Patients

>

> * Tenofovir Antiviral Activity Similar in Lamivudine-Naive and

Lamivudine-Experienced Individuals With Chronic Hepatitis B

>

> * Switch to Tenofovir-Based Regimen Results Effective for Hepatitis B

Patients With Persistent Viremia Receiving Adefovir

>

> * Magnitude of HBsAg Decline on Treatment Predicts Posttreatment HBsAg

Clearance Following Peginterferon alfa-2a–Based Therapy

>

> * Long-term HBV DNA Suppression With Adefovir/Lamivudine Combination in

Chronic Hepatitis B Patients With Lamivudine Resistance

>

> * Long-term Entecavir Treatment Safe and Effective in Japanese

Treatment-Naive Chronic Hepatitis B Patients Through Year 3

>

> * HBeAg Seroconversion Sustained for 52 Weeks in Chronic Hepatitis B

Patients Treated With Telbivudine or Lamivudine Following Consolidation Therapy

>

> * Increasing Rates of Virologic Suppression Through Year 3 of Entecavir

Treatment in Chinese Cohort With Lamivudine Resistance

>

> These Capsule Summaries are located online at:

> http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Milan%202008.aspx

>

>

> Coming soon: CME-Certified Expert Analyses

>

>

> [http://images.clinicaloptions.com/img.asp?img=/logo/pim.gif]

>

> [http://images.clinicaloptions.com/img.asp?img=/cco/CCO_hep_logo.jpg]

>

> Physicians:

> Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care

Options, LLC.

>

> Nurses:

> Nursing contact hours provided through the cosponsorship of Postgraduate

Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute

for Medicine is accredited as a provider of continuing nursing education by the

American Nurses Credentialing Center's Commission on Accreditation.

>

> Pharmacists:

> Postgraduate Institute for Medicine is accredited by the Accreditation Council

for Pharmacy Education as a provider of continuing pharmacy education. Pharmacy

credit hours provided through the cosponsorship of Postgraduate Institute for

Medicine and Clinical Care Options, LLC.

>

> [http://clinicaloptions.com/assets/bin/logo/acpe-50.jpg]

>

> Supported by educational grants from Bristol-Myers Squibb; Gilead Sciences;

Pharmasset, Inc.;

> Tibotec, a Division of Janssen-Cilag; and Vertex.

>

>

[http://images.clinicaloptions.com/img.asp?img=/logo/new_logos/Bristol-MyersSqui\

bb.gif]

>

>

>

[http://images.clinicaloptions.com/img.asp?img=/logo/new_logos/Gileadwithtagline\

..gif]

>

>

> [http://images.clinicaloptions.com/img.asp?img=/logo/new_logos/pharmasset.gif]

>

>

>

>

>

[http://images.clinicaloptions.com/img.asp?img=/logo/new_logos/tibotec_janssen.g\

if]

>

>

> [http://images.clinicaloptions.com/img.asp?img=/logo/new_logos/Vertex.gif]

>

>

>

>

>

>

[http://images.clinicaloptions.com/img.asp?img=/House/Hep/Bookstore_Hep_00g.gif]

>

> Unsubscribe | Not a member yet? Click here | RSS | Hepatitis Podcasts |

Bookstore

>

> To ensure you receive Clinical Care Options educational materials by email,

> please add info@... to your contacts or address book.

>

> Copyright 2008 Clinical Care Options, LLC. All rights reserved. 1894 Preston

White Drive, Suite 110, Reston, VA 20191-5433

_________________________________________________________________

Make every e-mail and IM count. Join the i’m Initiative from Microsoft.

http://im.live.com/Messenger/IM/Join/Default.aspx?source=EML_WL_ MakeCount